Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
martedì, ottobre 06
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Haemonetics Corp
HAE
NYSE
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$103.66
-1.02
-0.97%
Ult. Agg.: Oct 6, 4:00 PM
$103.52
-1.16
-1.11%
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Privacy Manager
Haemonetics Financials
Haemonetics (HAE) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Haemonetics Q1 Adj. EPS $1.14 Beats $1.08 Estimate, Sales $339.380M Beat $327.894M Estimate
Benzinga Newsdesk
PRO
Haemonetics Widens FY2027 Sales Guidance from $1.410B-$1.427B to $1.401B-$1.441B vs $1.402B Est
Haemonetics (NYSE:HAE) widens FY2027 sales outlook from $1.410 billion-$1.427 billion to $1.401 billion-$1.441 billion vs $1.402 billion estimate.
Benzinga Newsdesk
PRO
Haemonetics Sees FY2027 Adj EPS $5.26-$5.31 vs $5.29 Est; Sees Sales $1.410B-$1.427B vs $1.394B Est
FISCAL 2027 GUIDANCEThe Company issued its fiscal 2027 GAAP total revenueand organic revenue growth guidance as follows: Total CompanyReported Revenue4 - 7%53rd week
Benzinga Newsdesk
PRO
Haemonetics Q4 Adj. EPS $1.29 Beats $1.27 Estimate, Sales $346.351M Beat $336.862M Estimate
Haemonetics (NYSE:HAE) reported quarterly earnings of $1.29 per share which beat the analyst consensus estimate of $1.27 by 1.57 percent. This is a 4.03 percent increase over earnings of $1.24 per share from the same
Benzinga Newsdesk
These Analysts Revise Their Forecasts On Haemonetics After Q3 Earnings
Avi Kapoor
PRO
Haemonetics Sees Revenue for 2026 FY is expected to down by -3 to -1% YoY
Haemonetics (NYSE:HAE) sees Revenue for 2026 FY is expected to down by -3 to -1% YoY
Benzinga Newsdesk
